Abstract
BackgroundCAR-T cell therapy has revolutionized the treatment of B-cell malignancies. However, the development of CAR-T therapies for T-cell malignancies has been slower, partially due to technical difficulties in T-cell antigen...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
